
Artelo Biosciences, Inc. (NASDAQ:ARTL) on Wednesday released interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial with ART27.13, the company’s peripherally acting cannabinoid receptor agonist for cancer anorexia-cachexia syndrome (CACS).
Affecting up to 80% of people living with cancer, CACS is marked by loss of appetite, weight loss and breakdown of muscle and fat.